Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

NCT04864834 | Completed Phase 3 Results FDA Drug

• 1 other identifier: CSOK583A12301
• Study Type: interventional
• Target: 485
• Locations: 15 countries
• Sites: 99

Brief Summary

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?

Conditions

Neovascular Age-related Macular Degeneration

Outcome Measures

Primary Outcomes (1)

• Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.

  The primary aim of the study is to demonstrate equivalence of change in BCVA score from Baseline at Week 8 between participants with nAMD treated with SOK583A1 and participants treated with Eylea EU. The primary analysis will be performed on the Per-Protocol Set (PPS), which is the most appropriate analysis set to use when testing for equivalence. ETDRS: Early Treatment Diabetic Retinopathy Study EU: European

  Change from baseline in mean BCVA score at Week 8

Secondary Outcomes (6)

• Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU

  Week 1, 4, 8, 24 and 52

• Similarity in the Anatomical Outcome Between SOK583A1 and Eylea EU

  Week 8 and 52

• Similarity of Efficacy Between SOK583A1 and Eylea EU in Terms of BCVA

  Week 24 and 52

• Similarity Between SOK583A1 and Eylea EU in Terms of Safety

  52 weeks

• Similarity Between SOK583A1 and Eylea EU in Terms of Immunogenicity

  Week 52

Other Outcomes (1)

• Analysis Systemic VEGF Concentrations in Patients Treated With Aflibercept

  Assessment at Week 48 (pre-dose) and Week 52

Study Arms (2)

SOK583A1 (40 mg/mL)

EXPERIMENTAL

Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

Biological: SOK583A1 (40 mg/mL)

Eylea EU (40 mg/mL)

ACTIVE COMPARATOR

IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48. EU: European

Biological: Eylea EU (40 mg/mL)

Interventions

SOK583A1 (40 mg/mL) BIOLOGICAL

IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

SOK583A1 (40 mg/mL)

Eylea EU (40 mg/mL) BIOLOGICAL

IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

Eylea EU (40 mg/mL)

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

Participants eligible for inclusion in this study must meet all of the following criteria: 1. Signed informed consent must be obtained prior to participation in the study 2. Participants must be 50 years of age or older at Screening 3. Anti-VEGF treatment-naive patients for either eye and systemically 4. Study eye diagnosed with active CNV lesions (type 1 and/ or type 2) secondary to AMD and/or Retinal Angiomatous Proliferation lesions (type 3), affecting the central subfield. Active CNV lesion is defined by the presence of leakage as evidenced by fluorescein angiography, and intra- or subretinal fluid as evidenced by optical coherence tomography, both confirmed by the CRC at Screening 5. Total area of CNV (including both classic and occult components) must comprise \> 50% of the total lesion area in the study eye, confirmed by the CRC at Screening 6. BCVA between 73 and 38 letters, both inclusive, in the study eye at Screening and Baseline using ETDRS testing charts 7. Willing and able to comply with all study procedures, and be likely to complete the study 8. Clear ocular media and adequate pupil dilatation in both eyes to permit good quality photographic imaging. Participants meeting any of the following criteria are not eligible for inclusion in this study. Ocular conditions and treatments: 1. Previous treatment with any anti-VEGF therapy in either eye or investigational drugs in study eye or fellow eye, at any time prior to Baseline 2. Participant has received any approved treatment for nAMD (other than vitamin and dietary supplements) in the study eye and at any time prior to Baseline 3. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more negative), ocular histoplasmosis syndrome, angioid streaks,choroidal rupture, or multifocal choroiditis in the study eye, assessed by imaging at screening by CRC and appropriately stated in the multi-modal eligibility confirmation report 4. Any active or suspected intraocular or periocular infection or suspected active intraocular inflammation (e.g infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in either eye at Screening or Baseline 5. Subfoveal fibrosis, atrophy, or scarring extending \> 50% of total lesion area in the study eye as assessed by the Investigator at Screening and confirmed by the CRC prior to randomization 6. Subretinal hemorrhage that is ≥ 50% of the total lesion area in the study eye, or if the subretinal hemorrhage involving the fovea is 1 or more disc areas (≥ 2.54 mm2 ) in size in the study eye, as assessed by Fluorescein Angiography (FA) and confirmed by the CRC 7. Retinal pigment epithelium (RPE) rip/tear in the study eye at Screening or Baseline 8. Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline 9. History or evidence of the following, in the study eye: * Intraocular (including cataract surgery) or refractive surgery within the 90 day period prior to Baseline. The yttrium aluminum garnet (YAG) posterior capsulotomy is allowed no later than 4 weeks prior to Baseline * Previous penetrating keratoplasty or vitrectomy * Previous panretinal photocoagulation * Previous photodynamic therapy * Previous submacular surgery or other surgical intervention for AMD * Retinal detachment or treatment or surgery for retinal detachment * Any history of macular hole of stage 2 and above * Prior trabeculectomy or other filtration surgery * Ocular trauma within the 6-months period prior to Baseline 10. History of hypersensitivity to any of the study treatments or its excipients, or clinically relevant sensitivity to fluorescein dye, as assessed by the Investigators 11. Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \> 25 mmHg on medication or according to Investigator's judgment at Screening or Baseline 12. Aphakia and/or absence of the posterior capsule in the study eye at Screening or Baseline, unless it occurred as a result of a YAG posterior capsulotomy in association with prior posterior chamber intraocular lens implantation 13. Intra or periocular use of corticosteroids in the study eye within a 6 month period prior to Baseline 14. Use of topical ocular corticosteroids in the study eye for 30 or more consecutive days within the 90 days period prior to Baseline 15. Previous therapeutic radiation near the region of the study eye 16. Concomitant conditions or ocular disorders in the study eye, including media opacities, cataract and diabetic macular edema, at Screening or Baseline which could, in the opinion of the Investigator, prevent response to study treatment or may confound interpretation of study results (efficacy and safety), compromise visual acuity or require medical or surgical intervention during the course of the study 17. Presence of amblyopia, amaurosis or ocular disorders with BCVA \<38 letters (ETDRS testing charts) in the fellow eye at Screening (except when due to conditions whose surgery may improve VA, e.g. cataract) 18. Presence of Scleromalacia in either eye 19. Participants requiring anti-VEGF treatment of the fellow eye at Baseline will not be eligible for the PK substudy Systemic conditions and treatments: 20. Previous systemic treatment with any anti-VEGF therapy 21. Use of systemic corticosteroids for 30 or more consecutive days within the 90 days prior to Baseline, with the exception of low stable doses of corticosteroids (defined as ≤ 10 mg prednisolone or equivalent dose used for 90 days or more). 22. Uncontrolled blood pressure defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening 23. Stroke or myocardial infarction during the 6-month period prior to Baseline 24. Participation in an investigational systemic drug, biologic, or device study within 30 days or duration of 5 half-lives of the investigational product (whichever is longer) prior to Baseline. Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary 25. Presence of infection at screening or active infection within 2 weeks before screening 26. Underlying advanced, severe and uncontrolled concomitant condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, inflammatory, infectious or gastrointestinal), physical examination finding, or clinical laboratory finding which in the opinion of the Investigator place the participant at unacceptable risk from participation in the study 27. History of a medical condition (including, but not limited to chronic disease immunosuppression, metabolic dysfunction, prior exposure to other drugs that may pose risk of infection or allergic reactions) that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product, or that might affect participant safety or interpretation of the study results. 28. Pregnant or nursing (lactating) women and women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 3 months after stopping the medication. Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. * Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant. * Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS).

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Sandoz: lead

Study Sites (102)

Sandoz Investigational Site

Phoenix, Arizona, 85021, United States

Location

Sandoz Investigational Site

Arcadia, California, 91006, United States

Location

Sandoz Investigational Site

Campbell, California, 95008, United States

Location

Sandoz Investigational Site

Encino, California, 91436, United States

Location

Sandoz Investigational Site

Fullerton, California, 92835, United States

Location

Sandoz Investigational Site

Glendale, California, 91203, United States

Location

Sandoz Investigational Site

Huntington Beach, California, 92647, United States

Location

Sandoz Investigational Site

Pasadena, California, 91107, United States

Location

Sandoz Investigational Site

Poway, California, 92064, United States

Location

Sandoz Investigational Site

Redlands, California, 92374, United States

Location

Sandoz Investigational Site

Sacramento, California, 95841, United States

Location

Sandoz Investigational Site

Fort Myers, Florida, 33912-7125, United States

Location

Sandoz Investigational Site

Pinellas Park, Florida, 33782, United States

Location

Sandoz Investigational Site

Plantation, Florida, 33324, United States

Location

Sandoz Investigational Site

Stuart, Florida, 34994, United States

Location

Sandoz Investigational Site

Marietta, Georgia, 30060, United States

Location

Sandoz Investigational Site

Oak Forest, Illinois, 60452, United States

Location

Sandoz Investigational Site

Hagerstown, Maryland, 21740, United States

Location

Sandoz Investigational Site

Albuquerque, New Mexico, 87102, United States

Location

Sandoz Investigational Site

Great Neck, New York, 11021, United States

Location

Sandoz Investigational Site

Liverpool, New York, 13088, United States

Location

Sandoz Investigational Site

Rochester, New York, 14620, United States

Location

Sandoz Investigational Site

Eugene, Oregon, 97401, United States

Location

Sandoz Investigational Site

Rapid City, South Dakota, 57701, United States

Location

Sandoz Investigational Site

Abilene, Texas, 79606, United States

Location

Sandoz Investigational Site

Arlington, Texas, 76012, United States

Location

Sandoz Investigational Site

Willow Park, Texas, 76087, United States

Location

Sandoz Investigational Site

Lynchburg, Virginia, 24502, United States

Location

Sandoz Investigational Site

Albury, New South Wales, 2640, Australia

Location

Sandoz Investigational Site

Liverpool, New South Wales, 2170, Australia

Location

Sandoz Investigational Site

Parramatta, New South Wales, 2150, Australia

Location

Sandoz Investigational Site

Sydney, New South Wales, 2000, Australia

Location

Sandoz Investigational Site

Adelaide, South Australia, 5000, Australia

Location

Sandoz Investigational Site

Melbourne, Victoria, 3002, Australia

Location

Sandoz Investigational Site

Linz, Upper Austria, 4021, Austria

Location

Sandoz Investigational Site

Linz, Upper Austria, A 4020, Austria

Location

Sandoz Investigational Site

Graz, A-8036, Austria

Location

Sandoz Investigational Site

Sofia, 1784, Bulgaria

Location

Sandoz Investigational Site

Pardubice, 530 02, Czechia

Location

Sandoz Investigational Site

Prague, 12808, Czechia

Location

Sandoz Investigational Site

Prague, 150 00, Czechia

Location

Sandoz Investigational Site

Marseille, Bouches-Du-Rhone, 13008, France

Location

Sandoz Investigational Site

Saint-Cyr-sur-Loire, Indre Et Loire, 37540, France

Location

Sandoz Investigational Site

Paris, 75015, France

Location

Sandoz Investigational Site

Düsseldorf, 40212, Germany

Location

Sandoz Investigational Site

Frankfurt am Main, 60596, Germany

Location

Sandoz Investigational Site

Freiburg im Breisgau, 79106, Germany

Location

Sandoz Investigational Site

Hanover, 30625, Germany

Location

Sandoz Investigational Site

Leipzig, 04103, Germany

Location

Sandoz Investigational Site

Mainz, 55131, Germany

Location

Sandoz Investigational Site

Marburg, 35043, Germany

Location

Sandoz Investigational Site

Budapest, HUN, 1204, Hungary

Location

Sandoz Investigational Site

Budapest, Pest County, 1134, Hungary

Location

Sandoz Investigational Site

Budapest, H-1085, Hungary

Location

Sandoz Investigational Site

Budapest, H-1136, Hungary

Location

Sandoz Investigational Site

Debrecen, 4032, Hungary

Location

Sandoz Investigational Site

Sopron, H-9400, Hungary

Location

Sandoz Investigational Site

Szeged, H-6720, Hungary

Location

Sandoz Investigational Site

Székesfehérvár, H-8000, Hungary

Location

Sandoz Investigational Site

Haifa, 3434104, Israel

Location

Sandoz Investigational Site

Jerusalem, 9112001, Israel

Location

Sandoz Investigational Site

Kfar Saba, 44281, Israel

Location

Sandoz Investigational Site

Lod, 6093000, Israel

Location

Sandoz Investigational Site

Petah Tikva, 4941492, Israel

Location

Sandoz Investigational Site

Rehovot, 7610001, Israel

Location

Sandoz Investigational Site

Tel Aviv, 6423906, Israel

Location

Sandoz Investigational Site

Nagakute, Aichi-ken, 480-1195, Japan

Location

Sandoz Investigational Site

Nagoya, Aichi-ken, 457 8510, Japan

Location

Sandoz Investigational Site

Nagoya, Aichi-ken, 466 8560, Japan

Location

Sandoz Investigational Site

Fukuoka, Fukuoka, 812-8582, Japan

Location

Sandoz Investigational Site

Kure, Hiroshima, 737-0029, Japan

Location

Sandoz Investigational Site

Amagasaki, Hyōgo, 660 8550, Japan

Location

Sandoz Investigational Site

Kobe, Hyōgo, 650-0017, Japan

Location

Sandoz Investigational Site

Inashiki-gun, Ibaraki, 300-0395, Japan

Location

Sandoz Investigational Site

Kagoshima, Kagoshima-ken, 890 8520, Japan

Location

Sandoz Investigational Site

Hamamatsu, Shizuoka, 430-8558, Japan

Location

Sandoz Investigational Site

Meguro-ku, Tokyo, 152-8902, Japan

Location

Sandoz Investigational Site

Taito-ku, Tokyo, 111-0051, Japan

Location

Sandoz Investigational Site

Ube, Yamaguchi, 755-8505, Japan

Location

Sandoz Investigational Site

Riga, 1002, Latvia

Location

Sandoz Investigational Site

Riga, LV-1007, Latvia

Location

Sandoz Investigational Site

Kaunas, Kaunas County, 50161, Lithuania

Location

Sandoz Investigational Site

Vilnius, LT-08661, Lithuania

Location

Sandoz Investigational Site

Krakow, Malopolska, 30-394, Poland

Location

Sandoz Investigational Site

Bydgoszcz, 85-631, Poland

Location

Sandoz Investigational Site

Lodz, 91-134, Poland

Location

Sandoz Investigational Site

Lublin, 20-079, Poland

Location

Sandoz Investigational Site

Wroclaw, 53-334, Poland

Location

Sandoz Investigational Site

Coimbra, 3000-548, Portugal

Location

Sandoz Investigational Site

Coimbra, 3030-363, Portugal

Location

Sandoz Investigational Site

Porto, 4200 319, Portugal

Location

Sandoz Investigational Site

Žilina, Slovak Republic, 010 01, Slovakia

Location

Sandoz Investigational Site

Bratislava, 821 01, Slovakia

Location

Sandoz Investigational Site

Bratislava, 83301, Slovakia

Location

Sandoz Investigational Site

Trenčín, 91171, Slovakia

Location

Sandoz Investigational Site

Bilbao, Basque Country, 48006, Spain

Location

Sandoz Investigational Site

Sant Cugat del Vallès, Catalonia, 08190, Spain

Location

Sandoz Investigational Site

Pamplona, Navarre, 31008, Spain

Location

Sandoz Investigational Site

Oviedo, Principality of Asturias, 33012, Spain

Location

Sandoz Investigational Site

Barcelona, 08021, Spain

Location

Sandoz Investigational Site

Barcelona, 8022, Spain

Location

Sandoz Investigational Site

Zaragoza, 50009, Spain

Location

Results Point of Contact

• Title: Clinical Disclosure Representative
• Organization: Sandoz

sandoz.disclosure@sandoz.com

+49 8024 / 908 0

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2021
• First Posted: April 29, 2021
• Study Start: May 12, 2021
• Primary Completion: July 7, 2022
• Study Completion: May 10, 2023
• Last Updated: March 26, 2024
• Results First Posted: March 26, 2024

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

IL (7); FR (3); LA (2); BU (1); US (28); ES (7); PT (3); CZ (3); PL (5); HU (8); LI (2); DE (7); AU (6); SL (4); JP (13)